Esophageal Cancer Palliative Care Compares SEMS and Radiotherapy Options

For patients with advanced esophageal cancer, the primary clinical goal is the alleviation of dysphagia—the impaired swallowing that defines the disease’s most debilitating symptom. The challenge for clinicians is balancing rapid symptom relief with the long-term risks of stent migration, tumor ingrowth, and radiation toxicity. Palliative therapies focus on alleviating core symptoms while preserving nutritional intake, minimising discomfort and enhancing quality of life.

Comparing SEMS and External Beam Radiotherapy

Endoscopic approaches, specifically the use of self-expanding metal stents (SEMS), are prized for their ability to rapidly restore swallowing function. These are endoscopic mesh devices that expand within the oesophageal lumen to alleviate malignant obstruction. However, these mesh devices are not without complication; they can lead to pain, perforation, and migration.

When radiotherapy is introduced to the equation, the results are mixed. A multicentre randomised trial, the ROCS trial (Palliative radiotherapy after oesophageal cancer stenting) published in The Lancet Gastroenterology & Hepatology in 2021, compared the use of SEMS alone against stent insertion followed by external beam radiotherapy (EBRT). The findings indicated that adding adjunctive radiotherapy did not significantly extend overall survival or reduce the early deterioration of dysphagia.

There is a specific benefit for high-risk patients, however. The same trial noted a lower incidence of bleeding complications in selected high-risk groups when radiotherapy was used alongside stenting.

EBRT vs. Intraluminal Brachytherapy

Not all radiotherapy is delivered the same way. Clinicians often choose between EBRT, which delivers ionising radiation from an external source to reduce tumour bulk, and intraluminal brachytherapy, where radioactive sources are positioned within or adjacent to oesophageal lesions to deliver high-dose radiation locally.

Matched-cohort investigations have highlighted a clear preference for the external approach. According to a study published in the Journal of Thoracic Oncology in 2020, Short-Course External Beam Radiotherapy Versus Brachytherapy for Palliation of Dysphagia in Esophageal Cancer: A Matched Comparison of Two Prospective Trials, EBRT achieves equivalent rates of dysphagia improvement compared to brachytherapy, but it does so with a faster onset of relief and a reduction in severe toxicities.

Neoadjuvant and Combined Modality Strategies

While palliative care focuses on quality of life, the approach for locally advanced esophageal cancer—where surgery or radiotherapy might offer a cure—is more aggressive. The prognosis for these patients remains poor due to the high likelihood of systemic metastatic disease and local recurrence.

The shift toward combined modality therapy is evident in the research. The use of chemoradiotherapy has been shown to be superior to using radiotherapy alone for the nonsurgical management of locoregional esophageal cancer. Strategies reviewed include:

• Preoperative chemotherapy.
• Preoperative concurrent chemotherapy combined with radiotherapy.
• Chemoradiotherapy as a definitive treatment in the absence of surgery.

While some trials suggest that preoperative chemoradiotherapy may outperform surgery alone, the exact role of these combined therapies in surgical management remains a subject of ongoing trials.

Multimodal Palliative Support and Ablation

True palliative success requires more than a single intervention. Optimal palliative care arises from interdisciplinary collaboration, tailoring interventions according to tumour characteristics, patient performance status and personal preferences. Multimodal regimens that combine stenting with systemic therapies or radiotherapy aim to prolong the window of symptom control, though this requires a careful balance to avoid cumulative toxicities.

Beyond radiation and stents, supportive care includes enteral feeding for nutritional management, analgesia, and the endoscopic dilatation of strictures. For recurrent lesions, cryospray ablation (CSA) has been utilized as a palliative treatment, specifically for squamous cell carcinoma of the esophagus, as detailed in the World Journal of Surgical Oncology (2007).

The efficacy of these interventions often depends on the specific hardware used. Recent analyses suggest that low-radial-force stents may reduce adverse events, particularly for patients who have already undergone radiotherapy, though these stents may be more susceptible to migration and tumor ingrowth.

Readers should consult qualified healthcare professionals to determine the appropriate treatment plan based on individual clinical needs.